metrogyl 10 mg/g gel vaginal
unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - metronidazolum - gel vaginal - 10 mg/g
ificipro 2 mg/ml soluţie perfuzabilă
unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - ciprofloxacinum - soluţie perfuzabilă - 2 mg/ml
metrogyl 10 mg/g gel
unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - metronidazolum - gel - 10 mg/g
metrogyl 5 mg/ml soluţie perfuzabilă
unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - metronidazolum - soluţie perfuzabilă - 5 mg/ml
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - neoplasmele prostatice, rezistent la castrare - produse radiofarmaceutice terapeutice - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.
givlaari
alnylam netherlands b.v. - givosiran - porphyrias, hepatice - diverse pentru tractul digestiv și metabolism - tratamentul acut de porfirie hepatică (ahp) la adulți și adolescenți cu vârsta de 12 ani și mai în vârstă.
locametz
novartis europharm limited - gozetotide - radionuclide imaging - produse radiofarmaceutice de diagnosticare - acest medicament este destinat exclusiv diagnosticului. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
forsef 1 g iv pulbere şi solvent pentru soluţie injectabilă/perfuzabilă
bilim ilac sanayi ve ticaret a.Ș. - ceftriaxonum - pulbere şi solvent pentru soluţie injectabilă/perfuzabilă - 1 g
zimaks 400 mg comprimate filmate
bilim pharmaceuticals a.Ș. - cefiximum - comprimate filmate - 400 mg
zimaks 100 mg/5 ml pulbere pentru suspensie orală
bilim pharmaceuticals a.Ș. - cefiximum - pulbere pentru suspensie orală - 100 mg/5 ml